BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Merck & Co., Inc. (MRK) to Pay $950 Million in Vioxx Settlement


11/22/2011 3:04:11 PM

Merck & Co. Inc. will pay $950 million to settle criminal and civil charges that it illegally promoted the painkiller Vioxx, the Justice Department announced Tuesday. The department said Merck will plead guilty to a misdemeanor offense and pay a $321.6 million criminal fine. The company is entering into a civil settlement in which it will pay $628 million to resolve additional allegations regarding off-label marketing of Vioxx and false statements about the drug's cardiovascular safety, the department said. The plea and settlement resolve a long-running investigation into Merck's marketing of Vioxx, which was withdrawn from the market in 2004.

Read at Wall Street Journal
Read at Forbes
Read at NPR News
Read at Reuters
Read at Financial Times
Read at USA Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES